Dopaminergic--GABA-ergic interaction in the nigrostriatal system
- PMID: 7348023
Dopaminergic--GABA-ergic interaction in the nigrostriatal system
Abstract
Unilateral electrolytic lesion at the level of the substantia nigra resulted in ipsilateral rotation after the administration of different dopaminergic agonists such as d-amphetamine (5 mg/kg), apomorphine (3 mg/kg) and piribedil (50 mg/kg) in rats. The influence of the alteration of the GABA level was investigated on circling behaviour induced either by the presynaptic DA-ergic agonist d-amphetamine or by the postsynaptic stimulant apomorphine. Aminooxyacetic acid (12.5 mg/kg) as a GABA-transaminase inhibitor, decreased the rotation elicited by d-amphetamine or apomorphine. Picrotoxin pretreatment (1.5 mg/kg) acted reversely on the circling behaviour elicited by the presynaptic DA-ergic agonist. Picrotoxin pretreatment showed a trend to decrease the rotation induced by the postsynaptic DA-ergic agonists apomorphine and piribedil. It is concluded that the action of GABA in this behavioural test might appear not only presynaptically but also postsynaptically in the nigrostriatal system and even in different forms.
Similar articles
-
Interactions of dopaminergic and GABAergic neurotransmission: impact of 6-hydroxydopamine lesions into the substantia nigra of rats.J Pharmacol Exp Ther. 1995 Oct;275(1):237-44. J Pharmacol Exp Ther. 1995. PMID: 7562556
-
Interrelations between dopaminergic and GABA-ergic transmitter mechanisms in apomorphine stereotypy.Acta Physiol Pharmacol Bulg. 1982;8(3):67-73. Acta Physiol Pharmacol Bulg. 1982. PMID: 6820612
-
Role of dopaminergic and GABA-ergic interactions in seizure susceptibility.Arch Int Pharmacodyn Ther. 1979 Oct;241(2):280-6. Arch Int Pharmacodyn Ther. 1979. PMID: 526081
-
Role of GABA in the striatal output system: globus pallidus, nucleus entopeduncularis, substantia nigra and nucleus subthalamicus.Adv Biochem Psychopharmacol. 1981;30:165-86. Adv Biochem Psychopharmacol. 1981. PMID: 7036675 Review. No abstract available.
-
Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.Pol J Pharmacol Pharm. 1976;28(5):469-93. Pol J Pharmacol Pharm. 1976. PMID: 796834 Review. No abstract available.